Cost-effectiveness of an in-development adult-formulated 21-valent pneumococcal conjugate vaccine in US adults aged 50 years or older-Reference-Cited by-同舟云学术

Cost-effectiveness of an in-development adult-formulated 21-valent pneumococcal conjugate vaccine in US adults aged 50 years or older

Published:2024-04 Issue:12 Volume:42 Page:3024-3032
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Altawalbeh Shoroq M.^ORCID,Wateska Angela R.,Nowalk Mary Patricia,Lin Chyongchiou J.,Harrison Lee H.^ORCID,Schaffner William^ORCID,Zimmerman Richard K.^ORCID,Smith Kenneth J.^ORCID

Funder

National Institute of Allergy and Infectious Diseases

National Institute of Allergy and Infectious Diseases Division of Intramural Research

Publisher

Elsevier BV

Reference34 articles.

1. Direct and indirect impact of 13-valent pneumococcal conjugate vaccine (PCV13) on invasive pneumococcal disease (IPD) among children and adults in the U.S. open forum;Pilishvili;Infect Dis,2017

2. Considerations for age-based and risk-based use of PCV15 and PCV20 among U.S. adults and proposed policy options;Kobayashi;ACIP meeting Pneumococcal Vaccines,2021

3. Kobayashi M, Farrar JL, Gierke R, et al. Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(4):109-17. doi: 10.15585/mmwr.mm7104a1.

4. Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase 1/2, randomised, double-blind, active comparator-controlled, multicentre;Platt;US-based trial Lancet Infect Dis,2023

5. Epidemiology of non-vaccine serotypes of Streptococcus pneumoniae before and after universal administration of pneumococcal conjugate vaccines;Du;Hum Vaccin Immunother,2021